Katrina Lee, MD
Dermatology · Los Angeles, CANPI 1255893517
Payments from drug & device makers
Across 51 payments — averaging $1650.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$74K
- Incyte Corporation$9K
- UCB, Inc.$638
- Dermavant Sciences, Inc.$179
- Amgen$160
- Galderma Laboratories, L.p.$150
- plus $411 from 6 others
What the payments were for
- Consulting fees$10,50074%
- Travel & lodging$1,46910%
- Food & beverage$2,29716%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $73,526 |
| Incyte Corporation | 12 | $9,136 |
| UCB, Inc. | 11 | $638 |
| Dermavant Sciences, Inc. | 1 | $179 |
| Amgen | 3 | $160 |
| Galderma Laboratories, L.p. | 1 | $150 |
| Sun Pharmaceutical Industries Inc. | 1 | $137 |
| Sanofi | 3 | $131 |
| Cipher Pharmaceuticals US LLC | 1 | $69 |
| Lilly USA, LLC | 1 | $29 |
| AbbVie | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,200 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 29 | $4,041 |
| Clindamycin Phosphate | 27 | $1,189 |
| Triamcinolone Acetonide | 41 | $508 |
| Doxycycline Monohydrate | 11 | $431 |
| Ketoconazole | 33 | $350 |
| Mupirocin | 23 | $144 |
| Cephalexin | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Los Angeles
- Howard SofenLos Angeles$16.1M
- April ArmstrongLos Angeles$6.2M
- Christopher HoLos Angeles$2M
- Pearl GrimesLos Angeles$1.6M
- Jonathan CotliarLos Angeles$1.4M
- Jennifer HsiaoLos Angeles$1.1M
- Derek JonesLos Angeles$1.1M
- Roger LoLos Angeles$727K
- Vivian LaquerIrvine$20.9M
- Raja SivamaniSacramento$11.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.